Clinical trials: Recurrent Epithelial Ovarian Cancer
Ovarian Cancer, Testicular Germ Cell Tumor
Combination Chemotherapy in Treating Patients With Germ Cell Tumors That Have Not Responded to Previous Cisplatin
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00002559
- Testing
- filgrastim, cisplatin, ifosfamide
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Ovarian Cancer
Efficacy and Safety of Paclitaxel (Albumin-bound) Combination With Carboplatin in Ovarian Cancer.
Epithelial ovarian cancer is the most fatal gynecological malignancy. Despite initial therapeutic response, the majority of advanced-stage patients relapse and eventually succumb to chemoresistant disease.
- Trial name
- NCT04661696
- Testing
- Paclitaxel (albumin-bound)
- Where
- China
- Volunteers
- 75 people
- Sponsor
- Chinese Academy of Medical Sciences
Ovarian Neoplasms, Recurrent Ovarian Carcinoma
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Phase Ib/II open label, multicenter study to evaluate the efficacy and safety of anti-PD-1 and VEGF bispecific antibody (AK112) combined with PARP inhibitor in patients with recurrent ovarian cancer.
- Conditions
- Ovarian Neoplasms, Recurrent Ovarian Carcinoma, Relapsed Ovarian Cancer, Ovarian Cancer
- Trial name
- NCT04999605
- Testing
- AK112 low dose, AK112 medium dose, AK112 high dose
- Where
- China
- Volunteers
- 8 people
- Sponsor
- Akeso
Ovarian Cancer, Recurrent Solid Tumors
ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors
This Phase I, open label, dose determining study of oral niraparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with metastatic or recurrent solid cancer.
- Trial name
- NCT06161493
- Testing
- ZEN003694, Niraparib
- Where
- United States
- Sponsor
- Haider Mahdi
Ovarian Cancer
A Study of Niraparib in Combination With Brivanib in Recurrent Ovarian Cancer
Open-label, cohort study to determine the safety and tolerability of the combination of daily niraparib and daily brivanib for one 28-day cycle in patients with advanced ovarian cancer.
- Trial name
- NCT03895788
- Testing
- niraparib, Brivanib
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Hunan Cancer Hospital
Endometrioid Cancer, Mucinous Ovarian Cancer
A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
The purpose of this research is to test the effectiveness and safety of the study drugs (VS-6766 and defactinib), and see what effects (good and bad) these drugs have on the patients with endometrioid cancer, mucinous ovarian…
- Conditions
- Endometrioid Cancer, Mucinous Ovarian Cancer, High Grade Serous Ovarian Cancer, Cervical Cancer
- Trial name
- DURAFAK (NCT05512208)
- Testing
- Avutometinib (VS-6766) + defactinib
- Where
- 4 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Oklahoma
Ovarian Cancer, Endometrial Cancer
Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer
The purpose of the first part of this study or the dose escalation portion of the study is to determine what dose of BKM120 and Abraxane is safe to give when the two drugs are used at the same time in patients who are diagnosed…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Recurrent Ovarian Cancer, Recurrent Endometrial Cancer
- Trial name
- NCT02117817
- Testing
- BKM120, Nabpaclitaxel
- Sponsor
- Rutgers, The State University of New Jersey
Ovarian Cancer
MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer
The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory epithelial ovarian cancer.
- Trial name
- NCT03916679
- Testing
- anti-MESO CAR-T cells
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Ovarian Cancer
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Chiauranib may stop the growth of tumor cells by blocking Aurora kinase B（Aurora B）、VEGFR/PDGFR/c-Kit、CSF-1R targets. This clinical trial is studying the efficacy and safety of chiauranib(50mg，QD，PO) works in treating patients…
- Trial name
- NCT03166891
- Testing
- Chiauranib
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Epithelial Ovarian Cancer
Health-Economic Evaluation of Early Diagnosis of Epithalial Ovarian Cancer Recurrence Using the ROMA Score: a Prospective Multicenter Randomized Trial
In this study, we hypothesize that calculating the ROMA score (CA125 + HE4 blood marker assay) will enable faster, more targeted diagnosis and management of epithelial ovarian cancer recurrence than the CA125 marker assay alone.
- Trial name
- ROMECO (NCT05991752)
- Testing
- ROMA score evaluation
- Sponsor
- University Hospital, Tours
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma
Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy
This phase II trial compares copanlisib and olaparib to standard of care chemotherapy in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that did not respond to previous platinum-based chemotherapy…
- Conditions
- Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma
- Trial name
- NCT05295589
- Testing
- Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging
- Where
- 5 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
This is a randomized phase II study, aimed at evaluating the efficacy (through progression free survival at 6 months) and safety of 5 different treatments involving atezolizumab, bevacizumab and/or acetylsalicylic acid in…
- Trial name
- NCT02659384
- Testing
- Bevacizumab, atezolizumab, acetylsalicylic acid
- Where
- 12 sites in France, Netherlands and 3 more
- Volunteers
- 122 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Ovarian Carcinoma
Whole-body Diffusion MRI for Staging, Response Prediction and Detecting Tumor Recurrence in Patients With Ovarian Cancer
The aim of this study is to assess whole body diffusion weighted imaging (WB-DWI) as a non-invasive method for accurate staging of patient suspected having ovarian cancer early treatment assessment detecting tumor recurrence
- Trial name
- S53580 (NCT01657747)
- Testing
- Whole body diffusion-weighted MRI
- Where
- Belgium
- Volunteers
- 350 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Recurrent Ovarian Cancer, HER2-negative
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
- Conditions
- Recurrent Ovarian Cancer, HER2-negative, Advanced Breast Cancer, TNBC
- Trial name
- HS-10502 (NCT06769425)
- Testing
- HS-10502 + NHA, HS-10502 + HS-20093, HS-10502+ Apatinib
- Where
- China
- Volunteers
- 157 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Cancer
Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy
RATIONALE: Vaccines may help the body build an effective immune response to kill cytomegalovirus infections. PURPOSE: This phase I trial is studying the side effects and best dose of vaccine therapy in treating patients who have…
- Trial name
- NCT00509691
- Testing
- cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Louisville
Cervical Cancer, Endometrial Cancer
MR-HIFU for Recurrent Gynaecological Cancer
The primary objective of this pilot study is to determine whether or not it is feasible to use MRgHIFU to treat symptomatic (pain, bleeding) recurrent pelvic malignancy with an acceptable safety profile when conventional…
- Conditions
- Cervical Cancer, Endometrial Cancer, Uterine Cancer, Ovarian Cancer
- Trial name
- HIFU-Gynae (NCT02714621)
- Testing
- Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)
- Where
- United Kingdom
- Volunteers
- 31 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00005952
- Testing
- filgrastim, temozolomide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites
Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer
The purpose of this study is to evaluate the safety and tolerability of BAX69 monotherapy given either as intraperitoneal (IP) infusion (Single-Route Arm); or as IP infusion after intravenous (IV) infusion (IV+IP) (Double-Route…
- Trial name
- NCT02540356
- Testing
- BAX69 Single-Route Arm, BAX69 Double-Route Arm
- Where
- 6 sites in United States
- Volunteers
- 2 people
- Sponsor
- Baxalta now part of Shire
Extragonadal Germ Cell Tumor, Ovarian Cancer
Carboplatin, Etoposide, Cyclophosphamide, and Autologous Bone Marrow Transplantation in Patients With Relapsed or Refractory Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with autologous bone marrow transplantation may help the body kill more tumor cells.
- Conditions
- Extragonadal Germ Cell Tumor, Ovarian Cancer, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00002943
- Testing
- carboplatin, cyclophosphamide, etoposide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer
First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors
TP-0903 is a novel oral inhibitor that targets AXL kinase and reverses the mesenchymal phenotype associated with advanced cancers.
- Conditions
- Advanced Solid Tumors, EGFR Positive Non-small Cell Lung Cancer, Colorectal Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT02729298
- Testing
- TP-0903
- Where
- 16 sites in United States
- Volunteers
- 177 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.